Related Experiment Video
Updated: Jul 27, 2026
07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
[Angiogenic gene therapy for ischemic heart disease]
1Department of Cardiology, Kyushu University School of Medicine.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|October 31, 1998
Summary
Exogenous angiogenic growth factors can promote collateral development, potentially saving heart muscle from hypoxia and improving function. Gene transfer of these factors shows promise for treating ischemic heart disease.
Area of Science:
- Cardiovascular Science
- Molecular Biology
- Regenerative Medicine
Context:
- Myocardial hypoxia, caused by coronary artery narrowing, triggers endogenous production of angiogenic peptides like fibroblast growth factors.
- These peptides stimulate the development of collateral blood vessels to restore supply to ischemic regions.
- Exogenous administration of angiogenic factors aims to enhance this natural process.
Purpose:
- To review recent advancements in angiogenic therapy for ischemic heart disease.
- To explore the potential of exogenous angiogenic growth factors in facilitating collateral development.
- To evaluate gene transfer as a strategy for delivering angiogenic factors to ischemic myocardium.
Summary:
- Hypoxia in the myocardium due to coronary artery narrowing stimulates the production of angiogenic peptides, such as fibroblast growth factors, to form collateral vessels.
- Exogenous administration of angiogenic growth factors can facilitate collateral development, potentially protecting the myocardium from hypoxia and improving cardiac function.
- Gene transfer studies demonstrate restored blood supply and enhanced function in ischemic myocardium, highlighting this approach as a viable therapeutic strategy for ischemic heart disease.
Impact:
- Angiogenic therapy, particularly through gene transfer, offers a promising new strategy for treating ischemic heart disease.
- Facilitating collateral development can preserve myocardial tissue and improve overall heart function in patients with coronary artery disease.
- This review provides insights into the progress and potential of angiogenic therapies in cardiovascular medicine.
Related Concept Videos
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...